Co-occurring addictive disorder and attention deficit hyperactivity disorder

The ASAM Principles of Addiction Medicine: Fifth Edition

Volumn , Issue , 2014, Pages

  Levin, Frances Rudnick ^a   Mariani, John J ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84931056287     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (237)

1. Barkley R. Attention-deficit hyperactivity disorder. New York: The Guilford Press, 2006.
2. Mariani JJ, Levin FR. Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict 2007;16(Suppl 1):45-54.
3. Carroll KM, Rounsaville BJ. History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 1993;34(2):75-82.
4. Levin FR, Evans SM, Vosburg SK, et al. Impact of attention-deficit hyperactivity disorder and other psychopathology on treatment retention among cocaine abusers in a therapeutic community. Addict Behav 2004;29(9):1875-1882.
5. Stratton J, Gailfus D. A new approach to substance abuse treatment. Adolescents and adults with ADHD. J Subst Abuse Treat 1998;15(2):89-94.
6. Sullivan M, Levin F. Attention deficit/hyperactivity disorder and substance abuse: diagnostic and therapeutic considerations, in adult attention deficit disorder: brain mechanisms and life outcomes. New York: New York Academy of Sciences, 2001.
7. White AM, Jordan JD, Schroeder KM, et al. Predictors of relapse during treatment and treatment completion among marijuana-dependent adolescents in an intensive outpatient substance abuse program. Subst Abuse 2004;25(1):53-59.
8. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(11):1313-1323.
9. Sharp SI, McQuillin A, Gurling HM. Genetics of attention-deficit hyperactivity disorder (ADHD). Neuropharmacology 2009;57(7-8):590-600.
10. Acosta MT, Arcos-Burgos M, Muenke M. Attention deficit/ hyperactivity disorder (ADHD): complex phenotype, simple genotype? Genet Med 2004;6(1):1-15.
11. Rubino T, Parolaro D. Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 2008;286(1-2 Suppl 1):S108-S113.
12. Zhou K, Chen W, Buitelaar J, et al. Genetic heterogeneity in ADHD: DAT1 gene only affects probands without CD. Am J Med Genet B Neuropsychiatr Genet 2008;147B(8):1481-1487.
13. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998;44(10):951-958.
14. Thapar A, O'Donovan M, Owen MJ. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet 2005;14 (Spec No. 2): R275-R282.
15. Shook D, Brady C, Lee PS, et al. Effect of dopamine transporter genotype on caudate volume in childhood ADHD and controls. Am J Med Genet B Neuropsychiatr Genet 2011;156B(1):28-35.
16. Franklin TR, Wang Z, Li Y, et al. Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. Addict Biol 2011;6:308-322.
17. Grzywacz A, Samochowiec J. [Case-control, family based and screening for DNA sequence variation in the dopamine transporter gene polymorphism DAT 1 in alcohol dependence]. Psychiatr Pol 2008;42(3):443-452.
18. Staller JA, Faraone SV. Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder. Expert Rev Neurother 2007;7(4):351-362.
19. Lai JH, Zhu YS, Huo ZH, et al. Association study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addiction. Brain Res 2010;1359:227-232.
20. Muglia P, Jain U, Macciardi F, et al. Adult attention deficit hyperactivity disorder and the dopamine D4 receptor gene. Am J Med Genet 2000;96(3):273-277.
21. George SR, Cheng R, Nguyen T, et al. Polymorphisms of the D4 dopamine receptor alleles in chronic alcoholism. Biochem Biophys Res Commun 1993;196(1):107-114.
22. Comings DE, Gonzalez N, Wu S, et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet 1999;88(4):358-368.
23. Lasky-Su J, Neale BM, Franke B, et al. Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B Neuropsychiatr Genet 2008;147B(8):1345-1354.
24. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009;126(1):51-90.
25. Lasky-Su J, Anney RJ, Neale BM, et al. Genome-wide association scan of the time to onset of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008;147B(8):1355-1358.
26. Elia J, Capasso M, Zaheer Z, et al. Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: suggestive association signals in ADRA1A. Psychiatr Genet 2009;19(3):134-141.
27. Ball D. Addiction science and its genetics. Addiction 2008;103(3):360-367.
28. Wang JC, Kapoor M, Goate AM. The genetics of substance dependence. Annu Rev Genomics Hum Genet 2012;13:241-261.
29. Sowell ER, Thompson PM, Welcome SE, et al. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet 2003;362(9397):1699-1707.
30. Arnsten AF. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 2006;67(Suppl 8):7-12.
31. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 2011;12(11):652-669.
32. Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. Ambul Pediatr 2007;7(1 Suppl):73-81.
33. Seidman LJ, Valera EM, Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(11):1263-1272.
34. Castellanos FX, Lee PP, Sharp W, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002;288(14):1740-1748.
35. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry 2005;57(11):1273-1284.
36. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381.
37. Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 2007;64(11):1575-1579.
38. McCormick MC, Workman-Daniels K, Brooks-Gunn J. The behavioral and emotional well-being of school-age children with different birth weights. Pediatrics 1996;97(1):18-25.
39. Manzardo AM, Madarasz WV, Penick EC, et al. Effects of premature birth on the risk for alcoholism appear to be greater in males than females. J Stud Alcohol Drugs 2011;72(3):390-398.
40. Braun JM, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect 2006;114(12):1904-1909.
41. Rydell M, Cnattingius S, Granath F, et al. Prenatal exposure to tobacco and future nicotine dependence: population-based cohort study. Br J Psychiatry 2012;200(3):202-209.
42. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2(2):104-113.
43. Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry 2000;39(11):1424-1431.
44. Barkley RA, Fischer M, Smallish L, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002;111(2):279-289.
45. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000;157(5):816-818.
46. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163(4):716-723.
47. Simon V, Czobor P, Balint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009;194(3):204-211.
48. Weiss RD, Mirin SM, Griffin ML, et al. Psychopathology in cocaine abusers. Changing trends. J Nerv Ment Dis 1988;176(12):719-725.
49. Wilens TE, Dodson W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry 2004;65(10):1301-1313.
50. Wood D, Wender PH, Reimherr FW. The prevalence of attention deficit disorder, residual type, or minimal brain dysfunction, in a population of male alcoholic patients. Am J Psychiatry 1983;140(1):95-98.
51. Levin FR, Evans SM, Kleber HD. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend 1998;52(1):15-25.
52. Clure C, Brady KT, Saladin ME, et al. Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice. Am J Drug Alcohol Abuse 1999;25(3):441-448.
53. Schubiner H, Tzelepis A, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000;61(4):244-251.
54. King VL, Brooner RK, Kidorf MS, et al. Attention deficit hyperactivity disorder and treatment outcome in opioid abusers entering treatment. J Nerv Ment Dis 1999;187(8):487-495.
55. Levin FR, Evans SM, McDowell DM, et al. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998;59(6):300-305.
56. Rounsaville B, Carroll K. Psychiatric disorders in treatment-entering cocaine abusers. NIDA Res Monogr 1991;110:227-251.
57. van Emmerik-van Oortmerssen K, van de Glind G, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend 2012;122(1-2):11-19.
58. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511-2518.
59. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51(1):8-19.
60. Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995;152(11):1652-1658.
61. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993;150(12):1792-1798.
62. Pomerleau OF, Downey KK, Stelson FW, et al. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995;7(3):373-378.
63. Tercyak KP, Lerman C, Audrain J. Association of attention-deficit/ hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. J Am Acad Child Adolesc Psychiatry 2002;41(7):799-805.
64. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 2005;62(10):1142-1147.
65. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998;31(6):533-544.
66. Gehricke JG, Hong N, Wigal TL, et al. ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD. Pharmacol Biochem Behav 2011;98(3):485-491.
67. Levin FR, Upadhyaya HP. Diagnosing ADHD in adults with substance use disorder: DSM-IV criteria and differential diagnosis. J Clin Psychiatry 2007;68(7):e18.
68. Levin FR, Bisaga A, Raby W, et al. Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence. J Subst Abuse Treat 2008;34(1):80-89.
69. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993;150(6):885-890.
70. Murphy KR, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: Implications of clinical diagnosis. J Atten Disord 1996;1:147-161.
71. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):617-627.
72. Stein MA, Sandoval R, Szumowski E, et al. Psychometric characteristics of the Wender Utah Rating Scale (WURS): reliability and factor structure for men and women. Psychopharmacol Bull 1995;31(2):425-433.
73. Kessler RC, Adler LA, Gruber MJ, et al. Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. Int J Methods Psychiatr Res 2007;16(2):52-65.
74. Levin FR, Evans SM, McDowell DM, et al. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis 2002;21(2):1-16.
75. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27(2):187-201.
76. Daigre C, Ramos-Quiroga JA, Valero S, et al. Adult ADHD Self-Report Scale (ASRS-v1.1) symptom checklist in patients with substance use disorders. Actas Esp Psiquiatr 2009;37(6):299-305.
77. Dakwar E, Mahony A, Pavlicova M, et al. The utility of attention-deficit/hyperactivity disorder screening instruments in individuals seeking treatment for substance use disorders. J Clin Psychiatry 2012;73(11):e1372-e1378.
78. Epstein JN, Johnson DE, Conners CK. Conner's Adult ADHD Diagnostic Interview for DSM-IV (CAADID). North Tonawanda, NY: Multi-Health Systems, Inc., 2001.
79. Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9(3):711-726.
80. Greenfield B, Hechtman L, Weiss G. Two subgroups of hyperactives as adults: correlations of outcome. Can J Psychiatry 1988;33(6):505-508.
81. Elkins IJ, McGue M, Iacono WG. Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry 2007;64(10):1145-1152.
82. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006;59(9):829-835.
83. Biederman J, Petty CR, Monuteaux MC, et al. Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry 2010;167(4):409-417.
84. Chang Z, Lichtenstein P, Larsson H. The effects of childhood ADHD symptoms on early-onset substance use: a Swedish twin study. J Abnorm Child Psychol 2012;40(3):425-435.
85. Molina BS, Pelham WE Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 2003;112(3):497-507.
86. Biederman J, Mick E, Faraone SV. Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder. J Pediatr 1998;133(4):544-551.
87. Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict 1998;7(2):156-163.
88. Gittelman R, Mannuzza S, Shenker R, et al. Hyperactive boys almost grown up. I. Psychiatric status. Arch Gen Psychiatry 1985;42(10):937-947.
89. Thompson LL, Riggs PD, Mikulich SK, et al. Contribution of ADHD symptoms to substance problems and delinquency in conduct-disordered adolescents. J Abnorm Child Psychol 1996;24(3):325-347.
90. Milberger S, Biederman J, Faraone SV, et al. Associations between ADHD and psychoactive substance use disorders. Findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 1997;6(4):318-329.
91. Crowley TJ, Mikulich SK, MacDonald M, et al. Substance-dependent, conduct-disordered adolescent males: severity of diagnosis predicts 2-year outcome. Drug Alcohol Depend 1998;49(3):225-237.
92. Brook DW, Brook JS, Zhang C, et al. Association between attention-deficit/hyperactivity disorder in adolescence and substance use disorders in adulthood. Arch Pediatr Adolesc Med 2010;164(10):930-934.
93. Pardini D, White HR, Stouthamer-Loeber M. Early adolescent psychopathology as a predictor of alcohol use disorders by young adulthood. Drug Alcohol Depend 2007;88(Suppl 1):S38-S49.
94. Flory K, Milich R, Lynam DR, et al. Relation between childhood disruptive behavior disorders and substance use and dependence symptoms in young adulthood: individuals with symptoms of attention-deficit/hyperactivity disorder and conduct disorder are uniquely at risk. Psychol Addict Behav 2003;17(2):151-158.
95. Mannuzza S, Klein RG, Addalli KA. Young adult mental status of hyperactive boys and their brothers: a prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1991;30(5):743-751.
96. Wilens TE, Martelon M, Joshi G, et al. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry 2011;50(6):543-553.
97. Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;50(7):565-576.
98. Dalley JW, Fryer TD, Brichard L, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007;315(5816):1267-1270.
99. Hoffman WF, Moore M, Templin R, et al. Neuropsychological function and delay discounting in methamphetamine-dependent individuals. Psychopharmacology (Berl) 2006;188(2):162-170.
100. Kelly TH, Robbins G, Martin CA, et al. Individual differences in drug abuse vulnerability: d-amphetamine and sensation-seeking status. Psychopharmacology (Berl) 2006;189(1):17-25.
101. Khantzian EJ. An extreme case of cocaine dependence and marked improvement with methylphenidate treatment. Am J Psychiatry 1983;140(6):784-785.
102. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985;142(11):1259-1264.
103. Cook EH Jr, Stein MA, Krasowski MD, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995;56(4):993-998.
104. Gill M, Daly G, Heron S, et al. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 1997;2(4):311-313.
105. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999;38(12):1474-1477.
106. Roman T, Rohde LA, Hutz MH. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder. Am J Pharmacogenomics 2004;4(2):83-92.
107. Froehlich TE, Epstein JN, Nick TG, et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50(11):1129-1139 e2.
108. Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999;354(9196):2132-2133.
109. Smalley S. Reframing ADHD in the genomic era. Psychiatr Times 2008;18:5. http://www.psychiatrictimes.com/adhd/ reframing-adhd-genomic-era.
110. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162(8):1403-1413.
111. Filipek PA, Semrud-Clikeman M, Steingard RJ, et al. Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. Neurology 1997;48(3):589-601.
112. Valera EM, Faraone SV, Murray KE, et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;61(12):1361-1369.
113. Jentsch JD, Roth RH, Taylor JR. Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action. Prog Brain Res 2000;126:433-453.
114. Wilens TE, Hahesy AL, Biederman J, et al. Influence of parental SUD and ADHD on ADHD in their offspring: preliminary results from a pilot-controlled family study. Am J Addict 2005;14(2):179-187.
115. Faraone SV, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry 2006;163(10):1720-1729; quiz 1859.
116. Faraone SV, Biederman J, Mick E, et al. Family study of girls with attention deficit hyperactivity disorder. Am J Psychiatry 2000;157(7):1077-1083.
117. Biederman J, Petty CR, Monuteaux MC, et al. Familial risk analysis of the association between attention-deficit/hyperactivity disorder and psychoactive substance use disorder in female adolescents: a controlled study. J Child Psychol Psychiatry 2009;50(3):352-358.
118. Paternite CE, Loney J, Salisbury H, et al. Childhood inattention-overactivity, aggression, and stimulant medication history as predictors of young adult outcomes. J Child Adolesc Psychopharmacol 1999;9(3):169-184.
119. Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104(2):e20.
120. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders? J Clin Psychiatry 2003;64(Suppl 11):9-13.
121. Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008;165(5):597-603.
122. Winters KC, Lee S, Botzet A, et al. A Prospective Examination of the association of stimulant medication history and drug use outcomes among community samples of ADHD youths. J Child Adolesc Subst Abuse 2011;20(4):314-329.
123. Goksoyr PK, Nottestad JA. The burden of untreated ADHD among adults: the role of stimulant medication. Addict Behav 2008;33(2):342-346.
124. Wilson JJ. ADHD and substance use disorders: developmental aspects and the impact of stimulant treatment. Am J Addict 2007;16(Suppl 1):5-11; quiz 12-13.
125. Carlezon WA Jr, Mague SD, Andersen SL. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry 2003;54(12):1330-1337.
126. Hermens DF, Williams LM, Clarke S, et al. Responses to methylphenidate in adolescent AD/HD: evidence from concurrently recorded autonomic (EDA) and central (EEG and ERP) measures. Int J Psychophysiol 2005;58(1):21-33.
127. Lee JS, Kim BN, Kang E, et al. Regional cerebral blood flow in children with attention deficit hyperactivity disorder: comparison before and after methylphenidate treatment. Hum Brain Mapp 2005;24(3):157-164.
128. Schweitzer JB, Lee DO, Hanford RB, et al. Effect of methylphenidate on executive functioning in adults with attention-deficit/hyper-activity disorder: normalization of behavior but not related brain activity. Biol Psychiatry 2004;56(8):597-606.
129. Pliszka SR, Glahn DC, Semrud-Clikeman M, et al. Neuroimaging of inhibitory control areas in children with attention deficit hyperactivity disorder who were treatment naive or in long-term treatment. Am J Psychiatry 2006;163(6):1052-1060.
130. Shafritz KM, Marchione KE, Gore JC, et al. The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. Am J Psychiatry 2004;161(11):1990-1997.
131. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 4th edition, DSM-IV, Text Revision. Washington, DC: American Psychiatric Association, 2000.
132. Applegate B, Lahey BB, Hart EL, et al. Validity of the age-of-onset criterion for ADHD: a report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry 1997;36(9):1211-1221.
133. Barkley RA, Biederman J. Toward a broader definition of the age-of-onset criterion for attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36(9):1204-1210.
134. Adler LA, Faraone SV, Spencer TJ, et al. The reliability and validity of self- and investigator ratings of ADHD in adults. J Atten Disord 2008;11(6):711-719.
135. Knivsberg AM, Andreassen AB. Behaviour, attention and cognition in severe dyslexia. Nord J Psychiatry 2008;62(1):59-65.
136. Faraone SV, Biederman J, Friedman D. Validity of DSM-IV subtypes of attention-deficit/hyperactivity disorder: a family study perspective. J Am Acad Child Adolesc Psychiatry 2000;39(3):300-307.
137. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, DSM-5. Washington, DC: American Psychiatric Association, 2013.
138. Spencer T, Biederman J, Wilens T, et al. Is attention-deficit hyperactivity disorder in adults a valid disorder? Harv Rev Psychiatry 1994;1(6):326-335.
139. Spitzer RL, Williams JBW. Classification in psychiatry. In: Kaplan HI, Sadock BJ, eds. Comprehensive textbook of psychiatry, 4th ed. Baltimore, MD: Williams & Wilkin, 1985:591-612.
140. Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 1990;323(20):1361-1366.
141. Cubillo A, Rubia K. Structural and functional brain imaging in adult attention-deficit/hyperactivity disorder. Expert Rev Neurother 2010;10(4):603-620.
142. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52(6):434-443.
143. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 2011;25(2): 157-169.
144. Maneeton N, Maneeton B, Srisurapanont M, et al. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci 2011;65(7):611-617.
145. Mayes SD, Calhoun SL, Crowell EW. Learning disabilities and ADHD: overlapping spectrum disorders. J Learn Disabil 2000;33(5):417-424.
146. Johnson DE, Waid LR, Anton RF. Childhood hyperactivity, gender, and Cloninger's personality dimensions in alcoholics. Addict Behav 1997;22(5):649-653.
147. Johnson DE, Epstein JN, Waid LR, et al. Neuropsychological performance deficits in adults with attention deficit/hyperactivity disorder. Arch Clin Neuropsychol 2001;16(6):587-604.
148. Gordon M, Barkley RA, Lovett BJ. Tests and observational measures, in attention-deficit hyperactivity disorder: handbook for diagnosis and treatment, 3rd ed. New York: Guilford Press, Inc., 2006:369-389.
149. Murphy KR, Gordon M. Assessment of adults with ADHD, in attention-deficit hyperactivity disorder: handbook for diagnosis and treatment, 3rd ed. New York: Guilford Press, Inc., 2006:425-450.
150. Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45(2):192-202.
151. Gascon GG, Johnson R, Burd L. Central auditory processing and attention deficit disorders. J Child Neurol 1986;1(1):27-33.
152. APA: DSM-5 Development: Attention Deficit/Hyperactivity Disorder 2013.
153. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):593-602.
154. Vergara-Moragues E, Gonzalez-Saiz F, Lozano Rojas O, et al. Diagnosing adult attention deficit/hyperactivity disorder in patients with cocaine dependence: discriminant validity of Barkley executive dysfunction symptoms. Eur Addict Res 2011;17(6):279-284.
155. Avois L, Robinson N, Saudan C, et al. Central nervous system stimulants and sport practice. Br J Sports Med 2006;40(Suppl 1):i16-i20.
156. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47(1):21-31.
157. Biederman J, Faraone SV, Keenan K, et al. Family-genetic and psychosocial risk factors in DSM-III attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1990;29(4):526-533.
158. Biederman J, Faraone SV, Keenan K, et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples. Arch Gen Psychiatry 1992;49(9):728-738.
159. Torgersen T, Gjervan B, Rasmussen K. Treatment of adult ADHD: is current knowledge useful to clinicans? Neuropsychiatr Dis Treat. 2008;4(1):177-186.
160. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010;71(6):754-763.
161. Koesters M, Becker T, Kilian R, et al. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009;23(7):733-744.
162. Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill Book Co., 2006.
163. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004;24(1):24-29.
164. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2001;58(8):775-782.
165. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23(4):419-427.
166. Office of Applied Studies. Results from the 2004 National Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2010.
167. McCabe SE, Teter CJ, Boyd CJ, et al. Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. J Adolesc Health 2004;35(6):501-504.
168. McCabe SE, Knight JR, Teter CJ, et al. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005;100(1):96-106.
169. Rabiner DL, Anastopoulos AD, Costello EJ, et al. The misuse and diversion of prescribed ADHD medications by college students. J Atten Disord 2009;13(2):144-153.
170. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health 2006;54(5):269-278.
171. Teter CJ, McCabe SE, LaGrange K, et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006;26(10):1501-1510.
172. Rostain AL, Ramsay JR. A combined treatment approach for adults with ADHD-results of an open study of 43 patients. J Atten Disord 2006;10(2):150-159.
173. Fredericks EM, Kollins SH. Assessing methylphenidate preference in ADHD patients using a choice procedure. Psychopharmacology (Berl) 2004;175(4):391-398.
174. Stoops WW, Glaser PE, Fillmore MT, et al. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 2004;18(4):534-543.
175. Rush CR, Essman WD, Simpson CA, et al. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol 2001;21(3): 273-286.
176. Hart CL, Ward AS, Haney M, et al. Methamphetamine self-administration by humans. Psychopharmacology (Berl) 2001;157(1):75-81.
177. Roache JD, Grabowski J, Schmitz JM, et al. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. J Clin Psychopharmacol 2000;20(1):61-68.
178. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160(11):1909-1918.
179. Findling RL. Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: a review. Clin Ther 2008;30(5):942-957.
180. Mao AR, Babcock T, Brams M. ADHD in adults: current treatment trends with consideration of abuse potential of medications. J Psychiatr Pract 2011;17(4):241-250.
181. Mariani JJ, Levin FR. Psychostimulant treatment of cocaine dependence. Psychiatr Clin North Am 2012;35(2):425-439.
182. Kollins SH, Rush CR, Pazzaglia PJ, et al. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998;6(4):367-374.
183. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163(3):387-395.
184. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45(4):408-414.
185. Collins SL, Levin FR, Foltin RW, et al. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend 2006;82(2):158-167.
186. Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 2005;66(3):294-299.
187. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53(2):112-120.
188. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2009;19(4):353-364.
189. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2001;21(2):223-228.
190. Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19(5):501-510.
191. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2012;24(9):755-768.
192. Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19(3):215-226.
193. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics 2005;115(6):1734-1746.
194. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35(10):1314-1321.
195. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158(2):282-288.
196. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005;57(7):793-801.
197. Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007;87(1):20-29.
198. Motavalli Mukaddes N, Abali O. Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Clin Neurosci 2004;58(1):92-95.
199. Olvera RL, Pliszka SR, Luh J, et al. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 1996;6(4):241-250.
200. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38(12):1551-1559.
201. Biederman J, Swanson JM, Wigal SB, et al. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry 2006;67(5):727-735.
202. Greenhill LL, Biederman J, Boellner SW, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45(5):503-511.
203. Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/ hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006;67(1):137-147.
204. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000;10(4):311-320.
205. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30(1):205-211.
206. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008;96(1-2):145-154.
207. Somoza EC, Winhusen TM, Bridge TP, et al. An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. J Addict Dis 2004;23(1):77-92.
208. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002;10(3):286-294.
209. Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006;81(2):137-148.
210. Riggs PD, Winhusen T, Davies RD, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry 2011;50(9):903-914.
211. Winhusen TM, Somoza EC, Brigham GS, et al. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010;714(12):1680-1688.
212. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001;21(5):522-526.
213. Shearer J, Wodak A, van Beek I, et al. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003;98(8):1137-1141.
214. Shearer J, Wodak A, Mattick RP, et al. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001;96(9):1289-1296.
215. White R. Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. Addiction 2000;95(2):229-238.
216. Mooney ME, Herin DV, Schmitz JM, et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2009;101(1-2):34-41.
217. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29(5):969-981.
218. Levin FR, Brooks DJ, Bisaga A, et al. Severity of dependence and motivation for treatment: comparison of marijuana- and cocaine-dependent treatment seekers. J Addict Dis 2006;25(1):33-41.
219. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006;11(8):625-639.
220. Riggs P, Winhusen TM. Randomized Controlled Trial Osmotic-Release Methylphenidate (OROS-MPH) attention deficit hyperactivity disorder in adolescents with substance use disorders. Presented at American Academy of Addiction Psychiatry 20th Annual Meeting. Los Angeles, CA, December 3-6, 2009.
221. Ciccone PE. Attempted abuse of concerta. J Am Acad Child Adolesc Psychiatry 2002;41(7):756.
222. Higgins ST, Delaney DD, Budney AJ, et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry 1991;148(9):1218-1224.
223. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56(12):1073-1086.
224. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007;46(8):989-1002.
225. March JS, Swanson JM, Arnold LE, et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol 2000;28(6):527-541.
226. Safren SA, Otto MW, Sprich S, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 2005;43(7):831-842.
227. Vidal-Estrada R, Bosch-Munso R, Nogueira-Morais M, et al. Psychological treatment of attention deficit hyperactivity disorder in adults: a systematic review. Actas Esp Psiquiatr 2012;40(3):147-154.
228. Safren SA, Sprich S, Mimiaga MJ, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 2010;304(8):875-880.
229. Weinstein CS. Cognitive remediation strategies: an adjunct to the psychotherapy of adults with attention deficit hyperactivity disorder. J Psychother Pract Res 1994;3:44-57.
230. Aviram RB, Rhum M, Levin FR. Psychotherapy of adults with comorbid attention-deficit/hyperactivity disorder and psychoactive substance use disorder. J Psychother Pract Res 2001;10(3):179-186.
231. Dees SM, Dansereau DF, Simpson DD. A visual representation system for drug abuse counselors. J Subst Abuse Treat 1994;11(6):517-523.
232. Dansereau DF, Joe GW, Simpson DD. Attentional difficulties and the effectiveness of a visual representation strategy for counseling drug-addicted clients. Int J Addict 1995;30(4):371-386.
233. Riggs PD, Hall SK, Mukulick-Gilbertson SK, et al. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry 2004;43(4):420-429.
234. Carpentier PJ, de Jong CA, Dijkstra BA, et al. A controlled trial of methylphenidate in adults with attention deficit/ hyperactivity disorder and substance use disorders. Addiction 2005;100(12):1868-1874.
235. Konstenius M, Jayaram-Lindstrom N, Beck O, et al. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010;108(1-2):130-133.
236. McRae-Clark AL, Carter RE, Killeen TK, et al. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict 2010;19(6):481-489.
237. Thurstone C, Riggs PD, Salomonsen-Sautel S, et al. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry 2010;49(6):573-582.